The post USD/CAD slides to 1.3530, pressured by bullish Oil and weak USD appeared on BitcoinEthereumNews.com. The USD/CAD pair attracts some follow-through sellersThe post USD/CAD slides to 1.3530, pressured by bullish Oil and weak USD appeared on BitcoinEthereumNews.com. The USD/CAD pair attracts some follow-through sellers

USD/CAD slides to 1.3530, pressured by bullish Oil and weak USD

The USD/CAD pair attracts some follow-through sellers for the third consecutive day and drops to its lowest level since October 2024 during the Asian session on Thursday. Spot prices currently trade around the 1.3540-1.3535 region, down 0.15% for the day, and seem vulnerable to decline further amid a combination of factors.

Crude Oil prices rise to a four-month high due to rising geopolitical risks and continued Chinese buying. Furthermore, a surprise decline in US inventories offsets concerns about oversupply and remains supportive of elevated prices. This, in turn, underpins the commodity-linked Loonie, which, along with a bearish US Dollar (USD), continues to exert downward pressure on the USD/CAD pair and validates the near-term negative outlook.

The USD Index, which tracks the Greenback against a basket of currencies, remains well within striking distance of a four-year low amid heightened economic and policy risk linked to US President Donald Trump’s decisions. Apart from this, bets that the US Federal Reserve (Fed) will lower borrowing costs during the latter half of 2026 and the underlying bullish sentiment weigh on the safe-haven buck, contributing to the USD/CAD pair’s slide.

As was widely expected, the US central bank left its key policy rate unchanged at the end of a two-day meeting on Wednesday. In the post-meeting press conference, Fed Chair Jerome Powell said that the incoming data had shown a clear improvement in the economic outlook. Traders, however, are still pricing in two more interest rate cuts by the Fed in 2026. Moreover, concerns about the Fed’s independence keep the USD bulls on the defensive.

Meanwhile, the Bank of Canada (BoC) said that elevated levels of economic and geopolitical uncertainty were behind its decision to hold interest rates for the second time on Wednesday. The BoC added further that the uncertainty is bleeding into economic predictions, which now run from cuts to hikes to holds for 2026. The outlook, however, does little to influence the Canadian Dollar (CAD), leaving the USD/CAD pair at the mercy of the USD.

Traders now look to the release of the usual Weekly Initial Jobless Claims data from the US, which could influence the USD demand. Apart from this, Oil price dynamics might contribute to producing short-term trading opportunities around the USD/CAD pair. Nevertheless, the aforementioned fundamental backdrop remains tilted in favor of bearish traders and suggests that the path of least resistance for spot prices is to the downside.

US Dollar Price Last 7 Days

The table below shows the percentage change of US Dollar (USD) against listed major currencies last 7 days. US Dollar was the strongest against the Canadian Dollar.

USDEURGBPJPYCADAUDNZDCHF
USD-2.41%-2.87%-3.41%-2.11%-3.91%-3.54%-3.76%
EUR2.41%-0.47%-1.01%0.30%-1.54%-1.16%-1.39%
GBP2.87%0.47%-0.53%0.78%-1.07%-0.68%-0.92%
JPY3.41%1.01%0.53%1.31%-0.54%-0.18%-0.40%
CAD2.11%-0.30%-0.78%-1.31%-1.83%-1.46%-1.69%
AUD3.91%1.54%1.07%0.54%1.83%0.39%0.15%
NZD3.54%1.16%0.68%0.18%1.46%-0.39%-0.24%
CHF3.76%1.39%0.92%0.40%1.69%-0.15%0.24%

The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the US Dollar from the left column and move along the horizontal line to the Japanese Yen, the percentage change displayed in the box will represent USD (base)/JPY (quote).

Source: https://www.fxstreet.com/news/usd-cad-slide-to-13530-lowest-since-october-2024-amid-bullish-oil-prices-and-weak-usd-202601290056

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26